Standard of Care Treatment and Surgical Options for CMUSE

Managing Cryptogenic Multifocal Ulcerous Stenosing Enteritis (CMUSE) is a balancing act between controlling active inflammation and managing the physical narrowings (strictures) that the disease leaves behind. Because there are no universal international guidelines, your care team will offer individualized options based on your symptoms, nutritional status, stricture anatomy, and local expertise; urgent complications like acute obstruction may bypass a medication-first approach ^[1][2].

Medical Management

The first goal of treatment is to heal the ulcers and stop the loss of blood and protein.

Corticosteroids

Corticosteroids (such as prednisone or budesonide) are the most common first-line treatment for CMUSE ^[3]. While they can be very effective at inducing remission, they have significant limitations in this disease:

• Steroid Resistance: In one small retrospective cohort study, over 55% of patients were found to be “steroid-resistant,” meaning the medication did not sufficiently control their symptoms ^[4].
• Steroid Dependence: Many patients find that their symptoms return as soon as the steroid dose is lowered, leading to a “relapsing-remitting” cycle ^[3][1].

Safety Note: Corticosteroids carry risks such as infection, elevated blood sugar, mood changes, and bone loss, and should not be stopped abruptly.

Steroid-Sparing Agents and Investigational Treatments

If steroids are not working or are causing too many side effects, your doctor may suggest “steroid-sparing” medications to help keep the disease in check over the long term, though much of this evidence comes from small case reports:

• Immunomodulators: Medications like azathioprine have been used with mixed results. While some patients find relief, others may experience side effects like pancreatitis or only partial improvement ^[5][6]. Azathioprine generally requires baseline genetic testing (TPMT/NUDT15) and ongoing monitoring of liver function and blood counts.
• Biologics and Targeted Small Molecules: Treatments that target specific parts of the immune system, such as TNF inhibitors (biologics like infliximab) or upadacitinib (an investigational targeted small-molecule JAK inhibitor), are currently being explored ^[7]. However, evidence for these is mostly limited to individual case reports, their long-term effectiveness in CMUSE is not yet fully understood, and they carry important infection risks ^[7][8]. Their use in CMUSE is off-label.

Procedural Treatment: Balloon Dilation

Because CMUSE tends to recur and can affect multiple spots in the small bowel, doctors prioritize bowel-preserving strategies. The goal is to keep as much of your small intestine intact as possible to prevent “short-bowel syndrome,” where the body can no longer absorb enough nutrients ^[9].

A key tool in this strategy is Endoscopic Balloon Dilation (EBD). During a specialized endoscopy (balloon-assisted enteroscopy), an experienced therapeutic endoscopist passes a small balloon into a stricture and inflates it to stretch the narrowing ^[10]. This can improve symptoms of obstruction without the need for surgery. However, EBD may not be permanent; some strictures are too tough or recur too quickly for dilation to be a long-term solution, and the procedure carries risks like bleeding and perforation ^[11][10]. It is not suitable for inaccessible or very long strictures.

Surgical Options

Surgery is generally reserved for situations where the disease has become unmanageable through other means. Common reasons for surgery include:

• Complete Obstruction: When a stricture has narrowed so much that food can no longer pass through ^[11].
• Retained Capsules: If a “pill camera” gets stuck in a stricture and cannot be removed endoscopically ^[10][12].
• Failure of Dilation: If a stricture is too long or keeps closing back up after dilation ^[11].

The most common procedure is a resection, where the narrowed segment of the bowel is removed. Another option in some cases is strictureplasty, where the bowel is cut and sewn in a way that widens the narrowing without removing any tissue.

Important Note on Recurrence: It is important to understand that surgery is not a “cure” for CMUSE. New ulcers and strictures frequently appear even after a successful operation. In one small group of patients, the median time to a relapse after surgery was approximately 32 months, though outcomes vary substantially from person to person ^[13]. Because of this high rate of recurrence, surgery is viewed as a way to manage complications rather than to eliminate the disease entirely ^[1][2].